PharmaTelevision - AstraZeneca: Geoff Collett explains how AZ are searching for local opportunities to deliver medicines for unmet needs.

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: AstraZeneca: Geoff Collett explains how AZ are searching for local opportunities to deliver medicines for unmet needs.

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Geoff Collett, Regional Business Development Director - Europe, Global Commercial Operations of AstraZeneca.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Geoff Collett's role as Regional business development Director,Europe

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BIO-Europe, in Duesseldorf in 2011. On this show I have Geoff Collett, who is Regional Director Business Development, Europe for AstraZeneca, welcome.

Geoff Collett:

Thank you.

Fintan Walton:

Geoff as I said you are a Regional Director for Business Development within Europe that role for AstraZeneca is obviously important for adding new products to the subsidiary companies within the AstraZeneca group I presume, so could you tell us give us some sort of indication of where you fit within the AstraZeneca organization?

Geoff Collett:

Sure, and be happy too, the regional role is a fairly recent role within AstraZeneca, these jobs were created probably around two-years ago when AstraZeneca was really looking at its business development organization. So clearly we have business development people focused on in the innovative medicines groups looking for some of the earlier stage technologies and products, but we've also decided to move business development a little closer to the customer so to speak, so these regional units were set-up and they're not large but they really serve to support the regional Vice-President and his team in terms of communicating the global externalization strategy and also defining what the components are from a regional strategy and that could be anywhere from it could be should we be buildings new plants say in Latin America, should we be doing peer-to-peer collaborations in Europe to leverage our sales infrastructure, and the third one would be potentially branded generic acquisitions or collaborations with companies in that business in Latin America for instance.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Geoff Collett

Director

At the time of recording this PTV interview Geoff Collett works as Regional Business Development Director, Europe, AstraZeneca. Geoff has over 20 years of experience in the pharmaceutical, biotechnology and the life sciences industries. He began his career in sales, and progressed through a number of sales and sales management roles before specializing in licensing and business development. During the past 15 years he has held senior management and leadership positions including; Director, Business Development and Planning at GlaxoWellcome, Vice President - Early Stage Investing at MDS Capital, Vice President, Corporate Development at Lorus Therapeutics and currently is Director, Business Development at AstraZeneca. During this time he has completed numerous transactions in North America, Europe and Latin America and has provided management and Board of Director services to early stage companies such as GeminX, Terragen Discovery and Cytochroma.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

AstraZeneca

AstraZeneca discovers, develops, and commercializes prescription medicines for cardiovascular, gastrointestinal, infection, neuroscience, oncology, and respiratory and inflammation diseases worldwide. Its products include Crestor for managing cholesterol levels; Seloken-ToprolXL for hypertension, heart failure, and angina; Atacand for hypertension and heart failure; Nexium for acid reflux; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in pediatric patients. The company's products also comprise SeroquelIR for schizophrenia and bipolar disorder: SeroqueXR for schizophrenia, bipolar disorder, and depressive disorder; Arimidex for breast cancer; Zoladex for prostate and breast cancer; and Symbicort for asthma and chronic obstructive pulmonary disease. In addition, the company develops and manages hospital-based outpatient cancer centers in the United States. AstraZeneca PLC markets its products primarily to primary care and specialist doctors, and other healthcare professionals through distributors or local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.